Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach

Monica Lupi1, Giada Matera, Davide Branduardi

  • 1Biophysics Unit, Laboratory of Anticancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

Cancer Research
|April 17, 2004
PubMed

Insights

Topotecan (TPT) affects ovarian cancer cells beyond S phase, impacting G1 and G2-M checkpoints. This study uses computational modeling to detail TPT

Area of Science:

  • Pharmacology
  • Cell Biology
  • Computational Biology

Background:

  • Topotecan (TPT) is a topoisomerase I inhibitor.
  • TPT is thought to primarily affect cells in the S phase during treatment.
  • Understanding TPT's cell cycle effects is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To quantitatively analyze the time and dose dependence of Topotecan's effects on cell cycle controls.
  • To reconstruct the detailed sequence of events following Topotecan treatment.
  • To investigate the impact of Topotecan on cells treated outside of the S phase.

Main Methods:

  • Utilized a novel method combining experimental design with computer simulation.
  • Studied an ovarian cancer cell line's response to Topotecan treatment.
  • Analyzed dose-dependent kinetics of cell cycle block, recycling, and death.

Main Results:

  • Topotecan treatment (1 hour) impacts G1 and G2-M checkpoints, not just DNA synthesis.
  • Cell cycle effects, including block, recycling, and death, exhibit dose-dependent kinetics lasting over 3 days.
  • Cells treated outside of S phase contribute significantly to Topotecan's overall activity.
  • Simulations clarified auto-potentiation in repeated low-dose TPT treatments, increasing cytotoxicity.

Conclusions:

  • Topotecan's cellular effects are complex and extend beyond S-phase inhibition.
  • Computational modeling provides detailed insights into drug-induced cell cycle perturbations.
  • This approach can inform optimal drug scheduling and combination strategies for cancer treatment.